Overview Financials News + Filings Key Docs Charts Holdings Ownership Insiders
|
|
ClearPoint Neuro, Inc. (CLPT)
|
Add to portfolio |
|
|
|
| Price: |
$11.20
| | Metrics |
| OS: |
24.6
|
M
| |
-76
|
% ROE
|
| Market cap: |
$276
|
M
| |
-130
|
% ROIC
|
|
Net cash:
|
$16.5
|
M
| |
$0.67
|
per share
|
|
EV:
|
$259
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($20.2)
|
M
| |
|
|
|
EBIT
|
($21.1)
|
M
| |
|
|
| EPS |
($0.85)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| Revenues | 20.6 | 16.3 | 12.8 | 11.2 | 7.4 | 7.4 | 5.7 | 4.6 |
| Revenue growth | 26.1% | 27.0% | 14.4% | 52.5% | -0.4% | 28.4% | 25.1% | 27.5% |
| Cost of goods sold | 7.0 | 5.2 | 3.7 | 3.9 | 2.4 | 2.9 | 2.6 | 2.0 |
| Gross profit | 13.5 | 11.1 | 9.1 | 7.3 | 4.9 | 4.5 | 3.1 | 2.6 |
| Gross margin | 65.8% | 68.2% | 71.1% | 64.9% | 66.9% | 60.7% | 54.0% | 56.7% |
| Selling, general and administrative | 19.0 | 15.2 | 10.7 | 9.1 | 7.9 | 8.0 | 8.0 | 8.4 |
| Sales and marketing | 9.4 | 7.2 | 5.4 | 4.8 | 3.5 | 4.0 | 3.8 | |
| Research and development | 10.9 | 9.3 | 4.7 | 2.8 | 2.3 | 2.8 | 2.6 | 2.0 |
| EBIT | -16.3 | -13.4 | -6.2 | -4.6 | -5.2 | -6.3 | -7.5 | -7.7 |
| EBIT margin | -79.5% | -82.1% | -48.5% | -41.0% | -71.4% | -85.9% | -130.3% | -168.1% |
| Pre-tax income | -16.4 | -14.4 | -6.8 | -5.5 | -6.2 | -7.2 | -8.1 | -8.4 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -16.4 | -14.4 | -6.8 | -5.5 | -6.2 | -7.2 | -8.1 | -8.4 |
| Net margin | -80.0% | -88.4% | -52.9% | -49.4% | -83.8% | -97.1% | -140.4% | -183.9% |
| |
| Diluted EPS | ($0.68) | ($0.69) | ($0.43) | ($0.42) | ($0.56) | ($0.93) | ($2.93) | ($4.48) |
| Shares outstanding (diluted) | 24.2 | 20.7 | 15.8 | 13.2 | 10.9 | 7.7 | 2.8 | 1.9 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|